JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Apellis Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

28.6 1.89

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

28.02

Max

28.89

Schlüsselkennzahlen

By Trading Economics

Einkommen

50M

-42M

Verkäufe

12M

178M

Gewinnspanne

-23.615

Angestellte

705

EBITDA

50M

-30M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+28.14% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

30. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.2B

3.6B

Vorheriger Eröffnungskurs

26.71

Vorheriger Schlusskurs

28.6

Nachrichtenstimmung

By Acuity

34%

66%

108 / 371 Ranking in Healthcare

Apellis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Okt. 2025, 20:49 UTC

Ergebnisse

Correction to Thermo Fisher Article on Oct. 22

23. Okt. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. Okt. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. Okt. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. Okt. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. Okt. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. Okt. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. Okt. 2025, 22:49 UTC

Akquisitionen, Fusionen, Übernahmen

How Trump Sparked a New Era of State Capitalism -2-

23. Okt. 2025, 22:49 UTC

Akquisitionen, Fusionen, Übernahmen

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. Okt. 2025, 22:17 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. Okt. 2025, 21:41 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. Okt. 2025, 21:05 UTC

Ergebnisse

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

23. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

23. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. Okt. 2025, 20:35 UTC

Ergebnisse

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. Okt. 2025, 20:28 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. Okt. 2025, 20:15 UTC

Market Talk
Ergebnisse

Global Commodities Roundup: Market Talk

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q Adj EPS $1.71

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q Sales $5.52B

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q EPS $1.67

23. Okt. 2025, 20:09 UTC

Ergebnisse

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. Okt. 2025, 20:07 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

23. Okt. 2025, 20:07 UTC

Market Talk
Ergebnisse

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. Okt. 2025, 20:07 UTC

Ergebnisse

Blackstone Looks to IPOs for Investment Exits -- Update

23. Okt. 2025, 20:05 UTC

Ergebnisse

Intel 3Q Gross Margin 38.2% >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel: 4Q Guidance Excludes Altera >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel Sees 4Q Adj EPS 8c >INTC

Peer-Vergleich

Kursveränderung

Apellis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

28.14% Vorteil

12-Monats-Prognose

Durchschnitt 36.06 USD  28.14%

Hoch 60 USD

Tief 18 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Apellis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

10

Buy

6

Halten

1

Sell

Stimmung

By Acuity

108 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat